Drug Information

Drug General Information
Drug ID
D0CS2C
Former ID
DCL000487
Drug Name
AZD9056
Drug Type
Small molecular drug
Indication Chronic obstructive pulmonary disease [ICD9: 490-492, 494-496; ICD10:J40-J44, J47] Phase 2 [522096], [542771]
Company
AstraZeneca
Formula
C24H35ClN2O2
InChI
InChI=1S/C24H35ClN2O2/c25-22-5-4-17(3-1-6-26-7-2-8-28)12-21(22)23(29)27-16-24-13-18-9-19(14-24)11-20(10-18)15-24/h4-5,12,18-20,26,28H,1-3,6-11,13-16H2,(H,27,29)
InChIKey
HSQAARMBHJCUOK-UHFFFAOYSA-N
CAS Number
CAS 847254-30-2
PubChem Compound ID
10161381
PubChem Substance ID
15500954, 22559795, 40145537, 80766131, 85156823, 142665573, 198952266, 223366157, 223370279, 223929381, 230083676, 247769184
Target and Pathway
Target(s) P2X purinoceptor 7 Target Info Antagonist [550288]
KEGG Pathway Calcium signaling pathway
Neuroactive ligand-receptor interaction
Reactome The NLRP3 inflammasome
WikiPathways Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
References
Ref 522096ClinicalTrials.gov (NCT00520572) A 6-month Randomised, Double-blind, Open Arm Comparator, Phase IIb, With AZD9056, in Patients With Rheumatoid Arthritis (RA). U.S. National Institutes of Health.
Ref 542771(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7826).
Ref 550288Clinical pipeline report, company report or official report of AstraZeneca (2009).